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Objectives: The aim of this study was to evaluate how advances in CF management in France between 2000 and 2003 impacted CF-related costs.
Methods: The analysis of direct medical costs was done in 2000 and 2003 from the perspective of the French national healthcare insurance system.
The patients, 65 in 2000 and 64 in 2003, were followed-up in one pediatric and one adult CF reference center (CFRC). We quantified and valued
CF-related home and hospital care costs.
Results: We found an average cost of €16474/patient/year in 2000, and €22725 in 2003 (based on the 2003 euro value). Hospital care increased
from 15% of the total cost in 2000 to 22% in 2003. Medications accounted for 45% of the total cost for the two periods, with an average cost of
€7229/patient/year in 2000 and €10336 in 2003. Home intravenous antibiotic therapy accounted for 20% of the total cost for the two periods.
Conclusions: We highlighted an increase in CF care costs between 2000 and 2003, which might be related to the changes in practice patterns that
followed guidelines implementation, such as the use of new medications (dornase alpha and tobramycin) and more frequent follow-up in the
CFRC.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Practice guidelines; Economic evaluation; Cost-of-illness study1. Introduction
Cystic Fibrosis (CF) is the most frequent lethal autosomal
recessive disease in Caucasian populations [1]. This complex
disease is life-threatening and treatment is presently not
curative. Its management requires multidisciplinary care, both
in hospital and at home. Several treatments are prescribed in☆ Part of this work was presented at the 29th European CF Conference,
Copenhagen, Denmark on 15-18 June 2006.
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doi:10.1016/j.jcf.2008.02.004order to slow down the progression of the disease by treating CF
symptoms, acting upon failing metabolisms and their nutritional
consequences, and fighting lung infections and their conse-
quences on the respiratory function. These are often expensive,
since a part of them consist of antibiotics and innovative
therapeutics. Economic studies in the 1990s estimated CF-
related costs of care between $US6200 and $US16300 (1996
value) per patient per year [2].
Life expectancy for CF patients is constantly increasing,
reaching 30 years or more in industrialized nations today [3].
The reasons for this increase are constantly growing in the
knowledge of CF mechanisms, as well as in the advances made
in the different aspects of patient treatment. In the 1980s, Danishd by Elsevier B.V. All rights reserved.
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program model based on the early treatment of Pseudomonas
aeruginosa infections, with results deemed impressive in terms
of survival [4]. Afterwards, other countries adopted the Danish
model and many guidelines for CF management were imple-
mented. In France, the National Agency for Health Accreditation
and Evaluation published a Consensus Development Conference
for CF management in November 2002 essentially based on a
follow-up of patients once every 3 months in a reference center in
order to make the evaluation of nutrition and growth and to assess
pulmonary function and bacteriological status with adapted care
decision [5,6]. At the same time, regional care organizations were
set up, notably with the creation of CF reference centers (CFRC)
[7]. The national guidelines were diffused to all CFRC and
introduced in several professional meetings. Furthermore, in
France, few physicians are in charge of CF management and they
were actively involved in the drafting of the guidelines.
These have resulted in changes in practice patterns that are
likely to modify CF-related costs. Few economic studies on CF
management have been published, and none of them has
estimated the evolution of costs regarding the changes in clinical
practices. The aim of this study was to evaluate the trends in CF-
related costs following the advances inCFmanagement in France.
2. Materials and methods
2.1. Study population
Patients were selected from a cohort monitored in one
pediatric and one adult CFRC in the Rhône-Alpes area (one of
the largest in France). These centers followed-up roughly 400
children and adult patients in 2003. The economic study was
performed on two samples of these patients according to the
following inclusion criteria: for group 1, coverage by the local
French National Health Insurance (NHI) system in 2000 and
having filled out a patient-completed questionnaire in 2000; for
group 2, coverage by the local NHI and existing patient in the
NHI claims database in 2003. As group 1 patients may have
died or moved to another area after 2000, and CF children were
born between 2000 and 2003, some, but not all, of the patients
were the same between the two groups.
Newborns with the illness detected at birth in 2003 and patients
who had a lung transplant were not included in the study as the
guidelines for their care were different from those for other
patients, particularly in terms of clinical and therapeutic follow-up.
2.2. Clinical data
Information on sociodemographic data and CF character-
istics were collected from the patients' medical records.
2.3. Economic evaluation
The economic evaluation was performed according to the
criteria established by international rules [8]. The study was
conducted from the perspective of the NHI. Indeed, all medical
consumption related to CF management is fully covered by thehealthcare system in France. Costs were not discounted, as the
time horizon over which costs were considered was 1 year for
each group. Annual direct medical costs of CF care were
collected for each group.
Hospital care data concerned medical visits performed at the
CFRC by specialist physicians, outpatient hospitalizations
(admissions to short-stay units and day surgery with length of
stay of 1 day or less) and inpatient hospitalizations (admission
with length of stay ofmore than 2 days). These datawere gathered
for years 2000 and 2003 from the French hospital claims database
of Lyon's hospitals using the fixed price for diagnosis-related
groups, cross-referenced with patients' medical records.
Home care data concerned physician consultations (general
practitioners, pediatricians and specialist physicians), phy-
siotherapist consultations, nursing care, medications (excepted
for dornase alpha and inhaled tobramycin) and use of medical
devices, as well as lab and radiology tests. They were provided
by a patient-completed questionnaire for the patients of group 1
(data for year 2000 unavailable at the healthcare insurance
system) [9]. The questionnaire was prospectively filled out by
patients in the year 2000, over a 4-week period. The data were
thenmultiplied by 13 to obtain results for 1 year (52weeks). This
questionnaire comprised two parts: one on long-term care when
the patient was stable, and the other on particular treatment when
the patient's condition worsened or in unforeseen or emergency
situations. For group 2 (year 2003), data were obtained from the
NHI claims database. Data concerning the consumption of
dornase alpha and inhaled tobramycin were gathered from the
patients' medical records, as these medicines were dispensed by
hospital pharmacies only and were not available in the NHI
claims database. Data related to the costs of home IV-antibiotic
therapy and nebulizer rentals were provided by a local aid
association in charge of managing this part of the care.
In order to make both periods comparable, we worked with a
constant cost (in euros), taking 2003 as the year of reference. All
costs were valued according to the French nomenclature rates,
using the fixed prices in effect related to drugs, medical acts,
tests, and diagnosis-related groups. The cost of home IV-
antibiotic therapy considered was the fixed price negotiated with
NHI and included the price of medications and specific nursing.
Data was collected individually for each patient, enabling an
evaluation of an annual cost per source of expenditure and per
patient.
2.4. Statistical analysis
A comparative analysis of the patients' medical and
demographic characteristics between both groups was per-
formed, using a Pearson Chi-squared test for qualitative
variables, and a Student's t-test for quantitative variables.
A comparative analysis of CF-related costs was performed.
As costs were not Normally distributed, a Mann–Whitney U
nonparametric test was used. Economic results are presented in
terms of mean and 95% confidence interval calculated by the
nonparametric bootstrap method (1000 replications).
An α level of 0.05 was used to test for significance.
Statistical analysis was conducted using SPSS® Inc. software
Table 2
Patient management
2000 (n=65) 2003 (n=64)
% of
patients
Mean (max) % of
patients
Mean (max)
Home care
Medications including
Dornase alpha 32 – 42 –
Inhaled tobramycin 6 – 17 –
Pancreatic enzymes 85 – 73 –
Oral antibiotics 23 – 84 –
Inhaled colimycin 15 – 42 –
Physician
consultations
80 4.5 (24) 75 1.8 (7)
Physiotherapist
consultations
77 181.6 (364) 64 117.1 (471)
Nursing care – – 42 65.0 (161)
Medical devices 5 – 73 –
Lab and radiological
tests
9 1.4 (26) 36 1.1 (8)
IV-antibiotic therapy 31 1 (10) 34 1 (5)
Nebulizer rentals 34 – 52 –
Hospital care
CFRC visits⁎ 78 2.6 (12) – –
Outpatient
hospitalizations
46 1.2 (9) 83 5.0 (16)
Inpatient
hospitalizations
26 0.5 (6) 30 0.6 (4)
⁎ CFRC : CF reference center.
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2.5. Ethic approval
This study was approved by the French National Committee
of Information Technology and Rights.
3. Results
3.1. Patient characteristics
Sixty-five patients followed-up at the CFRC in 2000
answered the questionnaire and were affiliated with the local
office of the NHI (group 1).
In 2003, 70 patients from the population followed-up were
affiliated with the local office of the NHI. Of these patients, 5
children had been born in 2003 and had benefited from newborn
diagnosis by systematic detection, and one adult had benefited from
a lung transplant, leaving 64 patients in the eligible population
(group 2).
Thirty-three patients were common to both study groups.
The two groups did not present significantly different
characteristics (Table 1). Patients younger than 18 years old
accounted for 72% of group 1 and 69% of group 2. The mean
age for group 1 was 13, and that for group 2 was 15. All of the
patients had a mild to moderate form of the disease.
3.2. Medical consumption
The number of patients treated with dornase alpha and
inhaled tobramycin increased between the two studied periods,Table 1
Study group characteristics
2000 2003⁎
Number of patients 65 64
Children (%) 47 (72.3) 44 (68.8)
Adults (%) 18 (27.7) 20 (31.2)
Age (years)
Mean (standard deviation) 12.6 (10.2) 15.3 (10.5)
Min–Max 0–41.7 0.3–44.7
Age at diagnosis (years)
Mean (standard deviation) 2.7 (6.4) 3.1 (7.1)
Min–Max 0–37.0 0–37.0
Phenotype of genetic mutation
ΔF508del/ΔF508del (%) 31 (47.7) 22 (34.4)
ΔF508del/other (%) 19 (29.2) 18 (28.1)
Other/other (%) 9 (13.8) 14 (21.9)
Chronic infection with Pseudomonas aeruginosa (%) 18 (27.7) 12 (18.8)
Forced expired volume at 1 s (FEV1 %)
Mean (standard deviation) 70.7 (24.4) 71.1 (23.1)
Lung function-related severity level
Moderate: FEV1 between 30 and 50% (%) 7 (10.8) 6 (9.4)
Severe: FEV1b30% (%) 0 0
Chronic infection with Pseudomonas aeruginosa (%) 18 (27.7) 12 (18.8)
Pancreatic insufficiency (%) 45 (69.2) 45 (70.3)
Diabetes mellitus (%) 1 (1.5) 5 (7.8)
⁎ There was no statistical difference between the two groups.respectively from 32% in 2000 to 42% in 2003; and from 6% in
2000 to 17% in 2003 (Table 2).
Patients' hospital management also changed, with simple
physician consultations in the CFRC being replaced by
outpatient hospitalizations: these increased from an average of
1 outpatient hospitalization per patient per year in 2000 to 5
outpatient hospitalizations per patient per year in 2003.
A total of 59 home IV-antibiotic therapies were given in
2000 with a mean duration of 11.5 days per treatment; and 52 in
2003 with a mean duration of 13.3 days per treatment.
3.3. Cost-of-illness
The overall annual CF-related costs increased on average by
€6251 per patient between 2000 and 2003 (p=0.01; Table 3).
This concerned both home care (mean cost difference between
groups: €3693 per patient per year, non significant) and
hospital care (mean cost difference between groups: €2558 per
patient per year, pb10−3). Medications accounted for 45% of
the total cost for the two periods.
The home care cost segment was the largest, reaching 85% in
2000 and 78% in 2003. Medication accounted for more than half
of this (59% in 2000 and 52% in 2003), with an average increase
of €3107 per patient per year. The cost segment for respiratory
management accounted for 79% of the total medication cost in
2000, and rose to 88% in 2003. Within this category, the highest
costs were those of dornase alpha and inhaled tobramycin. These
also increased between the two groups on average by respectively
€1158 and€2190per patient per year. The increase in the inhaled
Table 3
Evaluation of direct medical costs for each group (in 2003 euros)
2000 (n=65) 2003 (n=64)
Mean cost (95% CI) a Mean cost (95% CI) a p b
Home care
Medications including 7229 (5541–9350) 10336 (7935–12390) NS
Dornase alpha 3788 (2791–5118) 4946 (3664–6045) NS
Inhaled tobramycin 1222 (305–2443) 3412 (1861–4653) 0.05
Pancreatic enzymes 916 (783–1083) 745 (593–927) NS
Oral antibiotics 259 (150–405) 363 (288–455) b10−3
Inhaled colimycin 145 (72–235) 208 (147–281) 0.05
Medical visits 246 (189–292) 35 (29–43) b10−3
Physiotherapy 2964 (2468–3355) 1681 (1300–2157) 0.02
Nursing 9 (0–26) 741 (539–1005) b10−3
Medical devices 13 (5–39) 1191 (868–1584) b10−3
Lab and radiological tests 69 (26–151) 48 (27–72) 0.003
IV-antibiotic therapy 3378 (1716–5625) 3565 (2282–5273) NS
Nebulizer rentals 75 (49–107) 77 (61–96) NS
Total home care costs 13981 (11373–16901) 17674 (14794–20654) NS
Hospital care
CFRC visits 354 (301–426) – – –
Outpatient hospitalizations 666 (479–917) 2808 (2400–3338) b10−3
Inpatient hospitalizations 1473 (792–2340) 2243 (1350–3280) NS
Total hospital care costs 2493 (1795–3395) 5051 (4092–6249) b10−3
Total CF-related costs 16474 (13685–19591) 22725 (19488–25870) 0.01
Abbreviations : CFRC: CF reference center; NS: non significant.
a 95% confidence intervals, calculated with the nonparametric bootstrap method.
b p-value, calculated with the Mann–Whitney U test.
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Proportionally, 52% of medication costs were due to dornase
alpha and 17% to inhaled tobramycin in 2000 (i.e. 69% of overall
medication costs), and 48%were due to dornase alpha and 33% to
inhaled tobramycin 2003 (i.e. 81% of overall medication costs).
Home IV-antibiotic therapy accounted for 24%of home care costs
in 2000 and 20% in 2003.
The hospital care segment costs increased from 15% in 2000
to 22% in 2003. Inpatient hospitalizations accounted for 59% of
the hospital care segment costs in 2000 and for 56% in 2003.
Outpatient hospitalizations were the main source of expenditure
explaining this increase, as the mean cost difference between
2000 and 2003 was €2142 per patient per year (pb10−3).
4. Discussion
This study outlines the increasing trends in CF-related costs,
on average from€16473 per patient per year in 2000 to€22724
per patient per year in 2003 (p=0.01). This increase was mostly
due to outpatient hospitalizations, as their mean number per
patient increased between 2000 and 2003, as well as to dornase
alpha and inhaled tobramycin, given the increasing number of
patients being treated with it. This evolution followed changes in
practice patterns that occurred during this period, related to the
set up of regional care organizations in October 2001 and French
guidelines for CF management in 2002.
The results of our cost-of-illness study are consistent with
those found in other published studies [10–16] despite
heterogeneity between the methods used for cost analysis, thestudied populations and the differences in the health care
systems [2]. The medical costs for CF in our study were in the
higher range of those estimated in other published studies. A
cost analysis of the long-term diseases among all French
patients covered by the NHI estimated an average refund of
€21543 per CF patient in 2004 [17].
However, the structures of CF-related costs were not
comparable from the previously published studies, with
different proportions of hospital care. Inpatient-related costs
were much higher in the other studies, reaching up to 47% in
Lieu's [13] where the population studied was similar to ours
(70% children). The emphasis on home care seems to be a
French characteristic. The French guidelines recommend home
care as much as possible [5]. However, in our study, we did not
observe a decrease in the number of hospitalizations nor an
increase in the number of home IV-antibiotic therapies. In the
Rhône-Alpes area, a collaboration between the hospital
pharmacies, the local aid associations in charge of managing
home IV-antibiotic therapy and the CFRC was set up, leading to
the creation of a health network [18]. Its set up took longer than
planned, however, and did not allow us to highlight a significant
change in home IV care.
The main source of expenditure that increased the total cost of
care was outpatient hospitalizations. This is explained by the fact
that the CFRC implementation resulted in patients having regular
visits. During these sessions, patients received a multidisciplinary
examination and treatments combining physiotherapy, nursing
care, nutritional supplements, and psychology consultations, in
addition to the usual clinical checkup and spirometric tests. This
407L. Huot et al. / Journal of Cystic Fibrosis 7 (2008) 403–408explains that hospital visits valued as physician consultations in
2000 (€23) were valued as outpatient hospitalizations in 2003
(€525). Furthermore, the average number of outpatient hospita-
lizations per patient increased, which suggests that the guidelines
recommending quarterly checkups were being followed. Johnson
et al. [19] have shown that the most intensive care, involving
regular frequent aftercare in a reference center, can be associated
with better patient health.
Dornase alpha and inhaled tobramycin-related costs play an
important role in home care costs, and logically increased along
with the number of patients treated with these medications
between 2000 and 2003. Clinical studies have shown that both
medications improve respiratory functions and should diminish
the number of exacerbations requiring antibiotic therapy [20,21].
Before the publication of French guidelines, the use of inhaled
tobramycin and dornase alphawas not systematic and varied from
CF center to CF center. As the guidelines recommended the use of
these treatments, they are now widely used. More particularly,
inhaled tobramycin is the first line treatment recommended in
France for maintenance antibiotic therapy [5].
The use of dornase alpha and inhaled tobramycin and the
development of patient aftercare in specialized healthcare
centers account for the high increase in the survival rate of
CF patients in recent years [22]. However, in spite of the
increase in the number of treated patients, we did not highlight a
decrease in the hospitalization rate.
Our study is unique because it takes into account the evolution
in disease management and new medications (i.e. dornase alpha
and inhaled tobramycin), unlike of all the economic studies on CF
management that were published in the 1990s [2]. The costing
method in this study was based on the actual utilisation of health
care resources and therefore is relatively accurate. For the year
2003, we have used data from the French NHI that allows for the
best estimation of home care costs from the perspective
considered. This database includes exhaustive individual infor-
mation on the affiliated patients, related to the refund of
consumption of all home medical services. We ascertained the
quality of the data collected as CF patients are refunded 100% on
account of the disabling and chronic nature of the disease.
The NHI data could not be retrieved for the year 2000, which
explains why we used data from a patient-completed ques-
tionnaire instead. The cost estimation for the year 2000 is
therefore likely to be underestimated, because patients often
have a tendency to minimize their healthcare consumption when
they answer self-administered questionnaires [23]. Data con-
cerning dornase alpha and inhaled tobramycin, which are the
main source of expenditure in home care and are ultimately
responsible for part of the overall increase in costs, was gathered
from the patients' medical records for both 2000 and 2003, thus
allowing for the same collection method and for a good estimate
of their costs. The use of the hospital claims database also
allowed for the best estimation of hospital care costs from the
perspective considered.
As none of the patients presented a severe stage of the
disease in our study, CF-related direct medical costs were
probably underestimated both for 2000 and for 2003. It has been
shown that CF-related costs increase as the disease progresses[11,13,14]. However, the demographic characteristics of our
sample were similar to the French CF population, with namely
62% of the patients being younger than 18 years of age in 2003
[24].
5. Conclusion
Our study highlights an increase in CF-related care costs in a
context of clinical publication of clinical guidelines and
implementation of CF reference centers. These practice patterns
allow for care that is better tailored to each patient in order to
improve the patient's quality of life as much as possible, and to
stabilize the disease in order to increase the chances of survival.
Such a study is of real interest for clinicians since they can
estimate the cost of their practice. Cost-effectiveness and cost-
utility assessments must now be undertaken to confirm the
importance of following the practice guidelines.
Acknowledgments
The authors gratefully acknowledge the contributions of Dr
François Clouet for having provided us the French National
Healthcare Insurance Agency data for the economic study; and
Stephen Martin for his help with the English writing.
This work was supported by the “Vaincre la Mucoviscidose"
association and the Lilly Institute funds for medico-economic
evaluation.
References
[1] Ratjen F, Doring G. Cystic fibrosis. Lancet Feb 22 2003;361(9358):681–9.
[2] Krauth C, Jalilvand N, Welte T, Busse R. Cystic fibrosis: cost of illness and
considerations for the economic evaluation of potential therapies.
PharmacoEcon 2003;21(14):1001–24.
[3] Schechter MS, Margolis P. Improving subspecialty healthcare: lessons
from cystic fibrosis. J Pediatr Sep 2005;147(3):295–301.
[4] Frederiksen B, Koch C, Hoiby N. Changing epidemiology of Pseudomonas
aeruginosa infection in Danish cystic fibrosis patients (1974–1995).
Pediatr Pulmonol Sep 1999;28(3):159–66.
[5] ANAES. Conférence de Concensus. Prise en charge du patient atteint de
mucoviscidose : Pneumologie et infectiologie, texte des recommandations.
Paris: Agence Nationale d'Accréditation et d'Evaluation en Santé; 2002.
[6] ANAES. Conférence de Concensus. Prise en charge du patient atteint de
mucoviscidose : Observance, nutrition, gastroentérologie et métabolisme,
texte des recommandations. Paris: Agence Nationale d'Accréditation et
d'Evaluation en Santé; 2002.
[7] Circulaire. DHOS /DGS/SD5/2001 n°502 du 22 octobre 2001 relative à
l'organisation des soins pour la prise en charge des patients atteints de
mucoviscidose.
[8] Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL.
Methods for the economic evaluation of health care programs. 3rd ed.
Oxford University Press; 2005.
[9] Horvais V, Touzet S, Francois S, Bourdy S, Bellon G, Colin C, et al. Cost
of home and hospital care for patients with cystic fibrosis followed up in
two reference medical centers in France. Int J Technol Assess Health Care
Fall 2006;22(4):525–31.
[10] Baumann U, Stocklossa C, Greiner W, von der Schulenburg JM, von der
Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis
patients. J Cyst Fibros Jun 2003;2(2):84–90.
[11] Ireys HT, Anderson GF, Shaffer TJ, Neff JM. Expenditures for care of
children with chronic illnesses enrolled in the Washington State Medicaid
program, fiscal year 1993. Pediatrics Aug 1997;100(2 Pt 1):197–204.
408 L. Huot et al. / Journal of Cystic Fibrosis 7 (2008) 403–408[12] Johnson JA, Connolly MA, Jacobs P, Montgomery M, Brown NE,
Zuberbuhler P. Cost of care for individuals with cystic fibrosis: a regression
approach to determining the impact of recombinant human DNase.
Pharmacotherapy Oct 1999;19(10):1159–66.
[13] Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients
with cystic fibrosis in a health maintenance organization. Pediatrics Jun
1999;103(6):e72.
[14] Robson M, Abbott J, Webb K, Dodd M, Walsworth-Bell J. A cost
description of an adult cystic fibrosis unit and cost analyses of different
categories of patients. Thorax Sep 1992;47(9):684–9.
[15] WildhagenMF, Verheij JB, Verzijl JG, Gerritsen J, BakkerW, Hilderink HB,
et al. The nonhospital costs of care of patients with CF in The Netherlands:
results of a questionnaire. Eur Respir J Nov 1996;9(11):2215–9.
[16] Wildhagen MF, Verheij JB, Verzijl JG, Hilderink HB, Kooij L, Tijmstra T,
et al. Cost of care of patients with cystic fibrosis in The Netherlands in
1990–1. Thorax Mar 1996;51(3):298–301.
[17] Vallier N, Weill A, Salanave B, Bourrel R, Cayla M, Suarez C, et al. Cost
of thirty long-term diseases for beneficiaries of the French general health
insurance scheme in 2004. Prat Organ Soins 2006;37(4):267–83.
[18] Bellon G. Centres and care networks for cystic fibrosis. Arch Pediatr Jun
2005;12(6):654–7.[19] Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME. Factors
influencing outcomes in cystic fibrosis: a center-based analysis. Chest Jan
2003;123(1):20–7.
[20] Iles R, Legh-Smith J, Drummond M, Prevost A, Vowler S. Economic
evaluation of Tobramycin nebuliser solution in cystic fibrosis. J Cyst
Fibros Sep 2003;2(3):120–8.
[21] Jones AP, Wallis CE. Recombinant human deoxyribonuclease for cystic
fibrosis. Cochrane Database Syst Rev (Online) 2003(3):CD001127.
[22] Slieker MG, Uiterwaal CS, Sinaasappel M, Heijerman HG, van der Laag J,
van der Ent CK. Birth prevalence and survival in cystic fibrosis: a national
cohort study in the Netherlands. Chest Oct 2005;128(4):2309–15.
[23] Jounieaux V, Guillaume C, Malka M, Wursthorn M, Girod I, Baron-
Papillon F. Medico-economic evaluation of a care management program
for asthmatic patients. Sante Publique (Vandoeuvre-les-Nancy, France)
2003 Dec;15(4):449–64.
[24] Observatoire National de la Mucoviscidose. Rapport sur la situation de la
mucoviscidose en France en 2002–2003. Institut National d'Etudes
Demographiques; 2003.
